Gilead Sciences was recently ordered to pay $2.54 billion to Merck to resolve a long-running patent dispute concerning its blockbuster patent sellers Sovaldi (earning Gilead $19 billion) and Harvoni (earning Gilead $23 billion) for hepatitis C treatment. The patent dispute… Continue Reading →
© 2024 Dawn Ellmore Employment's Blog — Powered by WordPress
Theme by Anders Noren — Up ↑